Summary
The company is brewing a specialized pipeline of therapeutics to potentially capture lucrative food allergy market share. And, lead molecule AR-101 recently posted stellar phase 3 (PALISADE) trial outcomes for peanut allergy.
Given the robust data for peanut allergy, the chances of other therapeutics (for walnut and egg) to work increased substantially.
Partnership deal with Sanofi/Regeneron to co-develop AR-101 with dupilumab in peanut-allergy patients lends further strength to the quality of this compound.
I believe that the greatest long-range investment profits are never obtained by investing in marginal companies. – The Father of Growth Investing (Philip Fisher)
Back on Oct. 24, 2017, we featured the bioscience expert, Biotech Beast(“BB”) in our Integrated BioSci Interview series and learned from the stellar trader scientist about a highly promising bioscience, Aimmune Therapeutics (NASDAQ:AIMT). The company is focusing on the development and commercialization of medicines to treat food allergies, including peanuts, walnuts, and eggs. In the past 52-weeks, the shares of Aimmune Therapeutics traded $10.48 (+53%) higher at $30.11. And, much of this appreciation is due to the robust underlying fundamental developments that we’ll elucidate in this research.
